CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
Converting Injectable Therapies to Combination Drug-Device Products
Published on:
Markus Hörburger
BioPharm International, BioPharm International, Partnerships for Outsourcing May 2022, Volume 2022 eBook, Issue 2
Pages: 14–17
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
The global biopharma market has experienced a remarkable period of evolution and expansion. In that time, parenteral medications have become one of the industry’s most important innovation and growth drivers.
Fueled by a continuing shift toward at-home, self-administered care—an established trend accelerated by the COVID-19 pandemic—the rapid surge in demand for injectable therapies is set to continue in the coming years. Between 2020 and 2027, sales of parenteral medications are projected to expand from 53–57% of global market volume, with most of those gains taken away from oral drugs (1).
Read this article in BioPharm International's Partnerships for Outsourcing eBook.
Advertisement
About the author
Markus Hörburger is product and service manager Secondary Packaging & Device Assembly at Vetter.
Article details
BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 14–17
Citation
When referring to this article, please cite it as M. Hörburger, “Converting Injectable Therapies to Combination Drug-Device Products,” BioPharm International Partnerships for Outsourcing eBook (May 2022).
